Iron leads to memory impairment that is associated with a decrease in acetylcholinesterase pathways

Current Neurovascular Research

Volumn 7, Issue 1, 2010, Pages 15-22

  Perez, Vinícius Pieta ^a   De Lima, Maria Noêmia Martins ^a   Da Silva, Rosane Souza ^a   Dornelles, Arethuza Silva ^a   Vedana, Gustavo ^a   Bogo, Maurício Reis ^a,b   Bonan, Carla Denise ^a,b   Schröder, Nadja ^a,b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b National Institute for Translational Medicine INCT TM   (Brazil)

Author keywords

Acetylcholinesterase; Muscarinic cholinergic receptors; Neurodegeneration; Object recognition memory; Rat; Striatum

Indexed keywords

ACETYLCHOLINESTERASE; GALANTAMINE; IRON; OXOTREMORINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN REGION; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HIPPOCAMPUS; IRON THERAPY; LONG TERM MEMORY; MALE; MEMORY CONSOLIDATION; MEMORY DISORDER; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECOGNITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 77949699432     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720210790820172     Document Type: Article

References (69)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 1999; 341: 1989-95.
2. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-73.
3. Lynch T, Cherny R, Bush AI. Oxidative processes in Alzheimer's disease: the role of Abeta-metal interactions. Exp Gerontol 2000; 35: 445-51.
4. Schenck JF, Zimmerman EA, Li Z, et al. High-field magnetic resonance imaging of brain iron in Alzheimer disease. Top Magn Reson Imaging 2006; 17: 41-50.
5. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114: 1953-75.
6. Faucheux BA, Hirsch EC, Villares J, et al. Distribution of 125Iferrotransferrin binding sites in the mesencephalon of control subjects and patients with Parkinson's disease. J Neurochem 1993; 60: 2338-41.
7. Jellinger KA, Kienzl E, Rumpelmaier G, et al. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol 1993; 60: 267-72.
8. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006; 253: 26-32.
9. Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl 2006; 70: 133-42.
10. Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntingon's disease. Cell Mol Biol (Noisy-le-grand) 2000; 46: 821-33.
11. Hayflick SJ, Hartman M, Coryell J, Gitschier J, Rowley H. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol 2006; 27: 1230-3.
12. Salazar J, Mena N, Hunot S, et al. Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 2008; 105: 18578-83.
13. Moos T. Brain iron homeostasis. Dan Med Bull 2002; 49: 279-301.
14. Schröder N, Fredriksson A, Vianna MR, Roesler R, Izquierdo I, Archer T. Memory deficits in adult rats following postnatal iron administration. Behav Brain Res 2001; 24: 77-85.
15. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T. Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits. Parkisonism Relat Disord 2001; 7: 97-105.
16. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T. Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice. Toxicol Appl Pharmacol 1999; 159: 25-30.
17. Fredriksson A, Schröder N, Eriksson P, Izquierdo I, Archer T. Maze learning and motor activity deficts in adult mice induced by iron exposure during a critical postnatal period. Dev Brain Res 2000; 119: 65-74.
18. de Lima MN, Polydoro M, Laranja DC, et al. Recognition memory impairment and brain oxidative stress by postnatal iron administration. Eur J Neurosci 2005; 21: 2521-8.
19. Flicker C, Ferris SH, Crook T, Bartus RT. A visual recognition memory test for the assessment of cognitive function in aging and dementia. Exp Aging Res 1987; 13: 127-32.
20. Purdy KS, McMullen PA, Freedman M. Changes to the object recognition system in patients with dementia of the Alzheimer's type. Brain Cogn 2002; 49: 213-6.
21. Schiavetto A, Kohler S, Grady CL, Winocur G, Moscovitch M. Neural correlates of memory for object identity and object location: effects of aging. Neuropsychologia 2002; 40: 1428-42.
22. de Lima MN, Laranja DC, Caldana F, Bromberg E, Roesler R, Schröder N. Reversal of age-related deficits in object recognition memory in rats with l-deprenyl. Exp Gerontol 2005; 40: 506-11.
23. De-Mello N, Souza-Junior IQ, Carobrez AP. Pilocarpine prevents age-related spatial learning impairments in rats. Behav Brain Res 2005; 158: 263-8.
24. Iyo M, Namba H, Fukushi K, et al. Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 1997; 349: 1805-9.
25. Rinne JO, Kaasinen, V, Järvenpää T, et al. Brain acetylcholinesterase activity in mild cognitive impairments and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74: 113-5.
26. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of alterations in acetylcholinesterase in Alzheimer's disease. Neurosci Lett 2005; 380: 127-32.
27. Markowska AL, Olton DS, Givens B. Cholinergic manipulations in the medial septal area: age-related effects on working memory and hippocampal electrophysiology. J Neurosci 1995; 15: 2063-73.
28. Erkinjuntti T. Treatment options: the latest evidence with galantamine (Reminyl). J Neurol Sci 2002; 203-204: 125-30.
29. Gould TJ, Feiro OR. Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment. Behav Brain Res 2005; 165: 160-71.
30. Shinoe T, Matsui M, Taketo MM, Manabe T. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 2005; 25: 11194-200.
31. Prediger RD, De-Mello N, Takahashi RN. Pilocarpine improves olfactory discrimination and social recognition memory deficits in 24 month-old rats. Eur J Pharmacol 2006; 531: 176-82.
32. de Lima MN, Laranja DC, Caldana F, et al. Selegiline protects against recognition memory impairments induced by neonatal iron treatment. Exp Neurol 2005; 196: 177-83.
33. de Lima MN, Presti-Torres J, Caldana F, et al. Desferoxamine reverses neonatal iron-induced recognition memory impairment in rats. Eur Pharmacol 2007; 570: 111-4.
34. de Lima MN, Presti-Torres J, Garcia VA, et al. Amelioration of recognition memory impairment associated with iron loading or aging by the type 4-specific phosphodiesterase inhibitor rolipram in rats. Neuropharmacology 2008; 55: 788-92.
35. Gralewicz S, Lutz P, Wiaderna D, Tomas T. Alteration in behavioral sensitivity to amphetamine after treatments with oxotremorine effect of dose and test environment. Behav Brain Res 2003; 147: 163-73.
36. Dimitrova SD, Getova-Spassova DP. Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia. J Pharmacol 2006; 101: 199-204.
37. Srikumar BN, Raju TR, Shankaranarayana Rao BS. The involvement of cholinergic and noradrenergic systems in behavioral recovery following oxotremorine treatment to chronically stressed rats. Neuroscience 2006; 143: 679-88.
38. de Lima MN, Dias CP, Torres JP, et al. Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol Aging 2008; 29: 1052-9.
39. Rampon C, Tang YP, Goodhouse J, Shimizu E, Kyin M, Tsien JZ. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat Neurosci 2000; 3: 238-44.
40. de Lima MN, Luft T, Roesler R, Schröder N. Temporary inactivation reveals an essential role of the dorsal hippocampus in consolidation of object recognition memory. Neurosci Lett 2006; 405: 142-6.
41. Schröder N, O'Dell SJ, Marshall JF. Neurotoxic methamphetamine regimen severely impairs recognition memory in rats. Synapse 2003; 49: 89-96.
42. Belcher AM, Feinstein EM, O'Dell SJ, Marshall JF. Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 2008; 33: 1453-63.
43. Dias CP, De Lima MN, Torres J, et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007; 146: 1719-25.
44. Ellman GL, Courtney KD, Andres V, Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95.
45. da Silva RS, Richetti SK, Da Silveira,VG, et al. Maternal caffeine affects acetylcholinesterase in hippocampus of neonate rats. Int J Dev Neurosci 2008; 26: 339-43.
46. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of the protein-dye binding. Anal Biochem 1976; 72: 248-54.
47. Cognato G de P, Czepielewski RS, Sarkis JJ, Bogo MR, Bonan CD. Expression mapping of ectonucleotide pyrophosphatase/ phosphodiesterase 1-3 (E-NPP1-3) in different brain structures during rat development. Int J Dev Neurosci 2008; 26: 593-8.
48. Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 2006; 31: 369-76.
49. Schliebs R, Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 2006; 113: 1625-44.
50. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinotrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res 2007; 4: 340-50.
51. Razay G, Wilcock GK. Galantamine in Alzheimer's disease. Expert Rev Neurother 2008; 8: 9-17.
52. Villarroya M, García AG, Marco-Contelles J, López MG. An update on the pharmacology of galantamine. Expert Opin Investig Drugs 2007; 16: 1987-98.
53. Wang D, Noda Y, Zhou Y, et al. The allosteric potentiation of nicotinic acetylcholine receptors by galantamine ameliorates the cognitive dysfunction in β amyloid 25-35 i.c.v.-injected mice: involvement of dopaminergic systems. Neuropsychopharmacology 2007; 32: 1261-71.
54. Moriguchi S, Marszalec W, Zhao X, Yeh JZ, Narahashi T. Mechanism of action of galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004; 310: 933-42.
55. Lorrio S, Sobrado M, Arias E, Roda JM, García AG, López MG. Galantamine postischemia provides neuroprotection and memory recovery against transient global cerebral ischemia in gerbils. J Pharmacol Exp Ther 2007; 322: 591-9.
56. de Bruin N, Pouzet B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 2006; 85: 253-60.
57. Csernansky JG, Martin M, Shah R, Bertchume A, Colvin J, Dong H. Cholinesterase inhibitors ameliorate behavioral deficits induced by MK-801 in mice. Neuropsychopharmacology 2005; 30: 2135-43.
58. Blake MG, Boccia MM, Acosta GB, Höcht C, Baratti CM. Opposite effects of a single versus repeated doses of gabapentin on retention performance of an inhibitory avoidance response in mice. Neurobiol Learn Mem 2007; 87: 192-200.
59. Schroeder JP, Packard MG. Facilitation of memory for extinction of drug-induced conditioned reward: role of amygdala and acetylcholine. Learn Mem 2004; 11: 641-7.
60. Dal-Pizzol F, Klamt F, Frota ML, Jr, et al. Neonatal iron exposure induces oxidative stress in adult Wistar rat. Brain Res Dev Brain Res 2001; 130: 109-14.
61. Wang HY, Lee DHS, D'Andrea MR, Peterson PA, Shank RP, Reitz AB. β-Amyloid (1-42) binds to α7 nicotinic acetylcholine receptor with high affinity: implications for Alzheimer's disease pathology. J Biol Chem 2000; 275: 5626-32.
62. Tanaka K, Yagi T, Shimakoshi R, et al. Effects of galantamine on L-NAME-induced behavioral impairment in Y-maze task in mice. Neurosci Lett 2009; 462: 235-8.
63. Smith R, Chung H, Rundquist S, et al. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet 2006; 15: 3119-31.
64. Dere E, Zheng-Fischhöfer Q, Viggiano D, et al. Connexin31.1 deficiency in the mouse impairs object memory and modulates open-field exploration, acetylcholine esterase levels in the striatum, and cAMP response element-binding protein levels in the striatum and piriform cortex. Neuroscience 2008; 153: 396-405.
65. Broadbent NJ, Squire LR, Clark RE. Rats depend on habit memory for discrimination learning and retention. Learn Mem 2007; 14: 145-51.
66. Aosaki T, Tsubokawa H, Jshida A, Watanabe K, Graybiel AM, Kimura M. Responses of tonically active neurons in the primate's striatum undergo systematic changes during behavioral sensorymotor conditioning. J Neurosci 1994; 14: 3969-84.
67. Aosaki T, Graybiel AM, Kimura M. Effects of nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkey. Science 1994; 265: 412-5.
68. Apicella P. Leading tonically active neurons of the striatum from reward detection to context recognition. Trends Neurosci 2007; 30: 299-306.
69. Hofer A, Siedentopf CM, Ischebeck A, et al. The neural regions sustaining episodic encoding and recognition of objects. Brain Cogn 2007; 63: 159-66.